Swiss National Bank Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Swiss National Bank decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 6.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,127,900 shares of the company's stock after selling 215,000 shares during the quarter. Swiss National Bank owned about 0.28% of Teva Pharmaceutical Industries worth $68,939,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. Diversify Advisory Services LLC increased its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after purchasing an additional 664 shares during the period. Metis Global Partners LLC increased its holdings in shares of Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after purchasing an additional 860 shares during the period. DGS Capital Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock worth $246,000 after purchasing an additional 872 shares during the period. Finally, Williamson Legacy Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.7% in the fourth quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company's stock worth $1,274,000 after purchasing an additional 979 shares during the period. Institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Trading Down 1.2 %

Shares of NYSE:TEVA traded down $0.20 on Wednesday, reaching $16.29. 9,360,002 shares of the company traded hands, compared to its average volume of 12,760,757. The business's 50-day simple moving average is $18.09 and its 200 day simple moving average is $18.26. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The stock has a market capitalization of $18.46 billion, a P/E ratio of -11.23, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.55% of the stock is owned by insiders.

Analysts Set New Price Targets

TEVA has been the topic of several research analyst reports. Bank of America decreased their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Friday, March 7th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Finally, Barclays cut their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.